Annalisa Savardi

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Top Venues

Science advances

ACS pharmacology & translational science

Journal of medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Alberto Potenzieri, Sara Uccella, Deborah Preiti, Matteo Pisoni, Silvia Rosati, Chiara Lavarello, Martina Bartolucci, Doriana Debellis, Federico Catalano, Andrea Petretto, Lino Nobili, Tommaso Fellin, Valter Tucci, Luca A Ramenghi, Annalisa Savardi, Laura Cancedda
Early IGF-1 receptor inhibition in mice mimics preterm human brain disorders and reveals a therapeutic target. Science advances 10 (9) (2024)
Alberto Potenzieri, Sara Uccella, Deborah Preiti, Matteo Pisoni, Silvia Rosati, Chiara Lavarello, Martina Bartolucci, Doriana Debellis, Federico Catalano, Andrea Petretto, Lino Nobili, Tommaso Fellin, Valter Tucci, Luca A Ramenghi, Annalisa Savardi, Laura Cancedda
Early IGF-1 receptor inhibition in mice mimics preterm human brain disorders and reveals a therapeutic target. Science advances 10 (9) (2024)
Alberto Potenzieri, Sara Uccella, Deborah Preiti, Matteo Pisoni, Silvia Rosati, Chiara Lavarello, Martina Bartolucci, Doriana Debellis, Federico Catalano, Andrea Petretto, Lino Nobili, Tommaso Fellin, Valter Tucci, Luca A Ramenghi, Annalisa Savardi, Laura Cancedda
Early IGF-1 receptor inhibition in mice mimics preterm human brain disorders and reveals a therapeutic target. Science advances 10 (9) (2024)
Alberto Potenzieri, Sara Uccella, Deborah Preiti, Matteo Pisoni, Silvia Rosati, Chiara Lavarello, Martina Bartolucci, Doriana Debellis, Federico Catalano, Andrea Petretto, Lino Nobili, Tommaso Fellin, Valter Tucci, Luca A Ramenghi, Annalisa Savardi, Laura Cancedda
Early IGF-1 receptor inhibition in mice mimics preterm human brain disorders and reveals a therapeutic target. Science advances 10 (9) (2024)
Annalisa Savardi, Andrea Patricelli Malizia, Marco De Vivo, Laura Cancedda, Marco Borgogno
Preclinical Development of the Na-K-2Cl Co-transporter-1 (NKCC1) Inhibitor ARN23746 for the Treatment of Neurodevelopmental Disorders. ACS pharmacology & translational science 6 (1) (2023)
Annalisa Savardi, Andrea Patricelli Malizia, Marco De Vivo, Laura Cancedda, Marco Borgogno
Preclinical Development of the Na-K-2Cl Co-transporter-1 (NKCC1) Inhibitor ARN23746 for the Treatment of Neurodevelopmental Disorders. ACS pharmacology & translational science 6 (1) (2023)
Marco Borgogno, Annalisa Savardi, Jacopo Manigrasso, Alessandra Turci, Corinne Portioli, Giuliana Ottonello, Sine Mandrup Bertozzi, Andrea Armirotti, Andrea Contestabile, Laura Cancedda, Marco De Vivo
Design, Synthesis, In Vitro and In Vivo Characterization of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in Down Syndrome. Journal of medicinal chemistry 64 (14) (2021)